PCI Pharma Services has announced its acquisition of Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO and subsidiary of Ajinomoto Co., Inc. The transaction, set to finalise in May 2025, marks a strategic move by PCI to enhance its global presence and
Debiopharm Research & Manufacturing S.A. and Oncodesign Services have entered into a licensing agreement that grants the contract research organisation the rights to use Debiopharm’s proprietary AbYlink technology for preclinical applications. The collaboration will focus on advancing the development of novel cancer treatment
Silexion Therapeutics Corp., a clinical-stage biotechnology company focused on RNAi therapies, has announced a collaboration with Catalent for the development and manufacturing of SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The agreement will see Catalent undertake formulation development and
LOTTE BIOLOGICS has signed a manufacturing agreement with an Asia-based biotechnology company to produce a clinical-stage antibody-drug conjugate (ADC) candidate. The announcement, made on the 24th, marks the company’s first contract in this therapeutic area and the official launch of its
“We are privately owned by a Trust, which means all our profits are reinvested in the company. This translates to steady growth – maybe slower compared to other service providers, but we’re quite proud of that steady growth,” explains Franciane
Suanfarma, a global leader in the pharmaceutical industry, has appointed Pere Mañé Godina as its new Chief Executive Officer. With more than 30 years of experience in pharmaceutical operations and contract development and manufacturing (CDMO), Pere’s arrival signals a major step forward
Phlow Corp., an American pharmaceutical contract development and manufacturing organisation (CDMO), has announced a major expansion of its analytical laboratories, AI integration, and workforce in the United States. The company has more than doubled in size and now includes over
CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and API manufacturing company, has secured its first Drug Manufacturing Licence (DML) from China’s National Medical Products Administration (NMPA). The licence marks a major milestone in the company’s expansion in China and authorises
FUJIFILM Biotechnologies, a global CDMO for biologics, vaccines, and advanced therapies, has announced a $3 billion manufacturing supply agreement with Regeneron Pharmaceuticals, Inc. The 10-year partnership will see FUJIFILM provide US-based production of Regeneron’s biologic medicines, beginning later this year at its
Highly Potent Active Pharmaceutical Ingredients (HPAPIs) have emerged as a cornerstone of modern pharmaceutical development, revolutionizing targeted therapy approaches across multiple disease areas. These exceptionally potent compounds are increasingly explored as strategic solutions for improving treatment efficacy while minimizing dosage
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
